Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 10
Submit an article Journal homepage
120
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy

Courtney TateDepartment of Haematology, Princess Alexandra Hospital, Woolloongabba, Australia; ;University of Queensland, St Lucia, Australia; Correspondence[email protected]
View further author information
,
Melinda BurgessTranslational Research Institute, Woolloongabba, Australia; View further author information
,
Nigel A. McMillanMenzies Health Institute Queensland, School of Medical Sciences, Griffith University, Southport, Australia; View further author information
,
Nicholas A. SaundersTranslational Research Institute, Woolloongabba, Australia; View further author information
,
Catherine CheungTranslational Research Institute, Woolloongabba, Australia; ;School of Medical Sciences, Griffith University, Southport, AustraliaView further author information
,
Devinder GillDepartment of Haematology, Princess Alexandra Hospital, Woolloongabba, Australia; View further author information
&
Peter MolleeDepartment of Haematology, Princess Alexandra Hospital, Woolloongabba, Australia; ;University of Queensland, St Lucia, Australia; View further author information
 show all
Pages 2563-2567 | Received 27 Jul 2018, Accepted 04 Feb 2019, Published online: 25 Jun 2019

References

  • International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779–790.
  • Collins RJ, Verschuer LA, Harmon BV, et al. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol. 1989;71:343–350.
  • Ayroldi E, D'Adamio F, Zollo O, et al. Cloning and expression of a short Fas ligand: a new alternatively spliced product of the mouse Fas ligand gene. Blood. 1999;94:3456–3467.
  • Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777–1783.
  • Osorio LM, Aguilar-Santelises M, De Santiago A, et al. Increased serum levels of soluble Fas in progressive B-CLL. Eur J Haematol. 2001;66:342–346.
  • Hallek M, Fischer K, Fingerle-Rowson G, et al. International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open- label, phase 3 trial. Lancet. 2010;376:1164–1174.
  • Chai-Adisaksopha C, Brown JR. FCR achieves long-term durable remissions in patients with IGHV-mutated CLL. Blood. 2017;130:2278–2282.
  • Yan XJ, Dozmorov I, Li W, et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood. 2011;118:5201–5210.
  • Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97:256–263.
  • Anand M, Chodda SK, Parikh PM, et al. Dysregulated cytokine production by monocytes from chronic lymphocytic leukemia patients. Cancer Biother Radiopharm. 1998;13:43–48.
  • Sivina M, Hartmann E, Kipps TJ, et al. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). Blood. 2011;117:1662–1669.
  • Knipping E, Debatin KM, Stricker K, et al. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood. 1995;85:1562–1569.
  • Knipping E, Krammer PH, Onel KB, et al. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum. 1995;38:1735–1737.
  • Peter ME, Hadji A, Murmann AE, et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 2015;22:549–559.
  • Liu JH, Wei S, Lamy T, et al. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood. 2002;100:1449–1453.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.